---
document_datetime: 2023-09-21 21:14:39
document_pages: 22
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ranexa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: ranexa-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 46.0011056
conversion_datetime: 2025-12-17 14:49:24.518382
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Ranexa

Procedural steps taken and scientificinformation after the authorisation

| Application number   | Scope                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued²/ amended on   | Product Information affected3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------|-------------------------------------|-------------------------------------------|---------------------------------|-----------|
| N/0067               | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification) | 07/12/2021                          |                                           | PL                              |           |
| IA/0066/G            | Thiswasanapplicationforagroupofvariations.                                          | 27/10/2021                          | n/a                                       |                                 |           |

1 Notifications areissued for typeIvariations andArticle 61(3)notifications(unlesspartofa groupincluding a typeIIvariation or extensionapplicationora worksharing application).Opinions areissuedfor allotherprocedures.

3SmPC (Summary of Product Characteristics),Annex I, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| and/or limits of anAs, starting material/intermediate/reagent-Additionofanew specificationparametertothespecificationwith its correspondingtestmethod B.1.b.2.a-Change in testprocedureforAS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure B.1.b.1.c-Changeinthespecificationparameters and/orlimitsof anAs,starting material/intermediate/reagent-Additionofanew specification parameterto the specification with its correspondingtestmethod B.I.b.1.c-Changeinthespecificationparameters and/or limits of an As, starting material/intermediate/reagent-Additionofanew specificationparametertothespecificationwithits correspondingtestmethod B.I.b.1.c-Change in the specificationparameters and/orlimitsof anAs,starting material/intermediate/reagent-Additionofanew specificationparameterto the specification with its correspondingtestmethod B.I.b.1.c-Change in the specificationparameters and/orlimitsof anAs,starting material/intermediate/reagent-Additionofanew specification parameterto the specification with its correspondingtestmethod A.7-Administrativechange-Deletionof manufacturing sites A.4-Administrativechange-Changeinthename and/oraddressofamanufactureroranAsMFholder   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                    | intermediateusedinthemanufactureoftheAsor manufacturerofanovelexcipient A.4-Administrativechange-Changeinthename and/oraddressofamanufactureroranAsMFholder orsupplieroftheAs,startingmaterial,reagentor intermediateusedinthemanufactureoftheAsor manufacturerofanovelexcipient B.I.b.1.c-Changein the specification parameters and/orlimitsof anAs,starting material/intermediate/reagent-Additionofanew specification parameterto the specification with its correspondingtestmethod B.I.b.1.c-Changeinthespecificationparameters and/or limits of an As, starting material/intermediate/reagent-Addition ofanew specificationparametertothespecificationwithits correspondingtestmethod A.7-Administrativechange-Deletionof manufacturing sites B.1.b.2.a-Change in testprocedureforAS or startingmaterial/reagent/intermediate-Minor changestoan approvedtestprocedure B.1.b.1.c-Changeinthespecificationparameters and/or limits of an As, starting material/intermediate/reagent-Additionofanew specification parameterto the specification with its   |            |     |                                |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------|
| PSUSA/2611/ 202101 | PeriodicSafetyUpdateEu Singleassessment- ranolazine                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 30/09/2021 | n/a | PRACRecommendation-maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0064/G   | B.I.a.1.z-Change in the manufacturerof AS orof a startingmaterial/reagent/intermediateforAs-Other variation B.I.a.4.z-Change toin-process tests orlimits appliedduringthemanufactureoftheAs-Other variation B.1.b.1.c-Changeinthespecificationparameters and/orlimitsof anAs,starting material/intermediate/reagent-Additionofanew specification parameterto the specification with its correspondingtestmethod B.I.a.2.e-Changesinthemanufacturingprocessof theAs-Minor changeto therestrictedpartof an   | 02/06/2021   | n/a        |                                  | This was an applicationfora group of variations. ASMF   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|---------------------------------------------------------|
| Ⅱ/0063      | C.I.4 -Change(s)in the SPC,Labelling orPL due to newquality,preclinical,clinical orpharmacovigilance                                                                                                                                                                                                                                                                                                                                                                                                       | 08/10/2020   | 26/03/2021 | SmPC, Annex II, Labelling and PL | data                                                    |
|             | This was an applicationfora group of variations. B.I.b.2.a-Change in testprocedure for AS or startingmaterial/reagent/intermediate-Minor changesto anapprovedtestprocedure B.I.b.2.a-ChangeintestprocedureforASor starting material/reagent/intermediate-Minor changestoanapprovedtestprocedure                                                                                                                                                                                                            | 25/05/2020   | n/a        |                                  | IA/0062/G                                               |
| IA/0061     | A.7-Administrativechange-Deletionof                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 23/03/2020   | 26/03/2021 | Annex II and                     |                                                         |

<div style=\"page-break-after: always\"></div>

|          | manufacturingsites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0060  | B.I.d.1.a.4-StabilityofAS-Changeinthere-test period/storage period-Extension or introduction ofa re-testperiod/storageperiodsupportedbyrealtime data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 05/07/2019 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0059  | B.I.a.3.a-Changeinbatchsize(includingbatch size ranges)ofASorintermediate-Upto10-fold increasecomparedtotheoriginallyapprovedbatch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/05/2019 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1/0057/G | This was an applicationfora group of variations. Groupingof4typeIIvariationstoupdatesections 4.6and5.3oftheSmPCbasedonthefinalresults from4newnon-clinicalstudies(studiesTX-259- 2004,2005,2006 and 2007);studyTX-259-2006is anoral(gavage)studyoftheeffectsofranolazineon fertilityand earlyembryonicdevelopmentto implantationinrats,studyTX-259-2004:Anoral (Gavage) study of the effects of ranolazine on embryo/foetaldevelopmentinrabbits,studyTX-259- 2005:Anoral(Gavage)studyoftheeffectsof ranolazineonembryo/foetaldevelopmentinratsand studyTX-259-2007:Anoral(Gavage)studyofthe effectsofranolazineonpre-andpost-natal developmentincluding maternal functioninrats.In addition,theMarketingauthorisationholder(MAH) tookthe opportunitytoimplementthewarning on sodiumsaltinlinewiththerevisedannextotheEC | 28/03/2019 | 10/03/2020 | SmPC and PL | TheMAHsubmittedthefinalresultsfrom4newnon-clinical studies(studiesTX-259-2004,2005,2006 and 2007). Regarding pregnancy there are limited amountof data from theuseofranolazineinpregnant women.Studiesin animalsshowedembryotoxicity(seeSection5.3).The potentialriskforhumansisunknown.Ranexashouldnot be used duringpregnancyunlessclearlynecessary. Regardingbreast-feeding,itisunknownwhetherranolazine isexcretedinhumanbreastmilk.Available pharmacodynamic/toxicologicaldatainratshaveshown excretionofranolazineinmilk(fordetailsseeSection5.3). Arisktothesucklingchildcannotbeexcluded.Ranexa should not be used duringbreast-feeding. Inmaleandfemalerats,oraladministrationofranolazine thatproducedexposures(AuC)3.6-fold or6.6-foldhigher thanexpectedinhumans,respectively,hadnoeffecton fertility. Embryofetaltoxicity studies were conducted inrats and rabbits:noeffectwerenotedinrabbitfetuseswhen |

<div style=\"page-break-after: always\"></div>

|             | guideline on'Excipients in the labelling and package leafletofmedicinalproductsforhumanuse'in section2ofthepackageleaflet,andtoupdatethe contactdetailsofthelocalrepresentativesin Bulgaria,Slovenia andtheSlovakrepublicin the Package Leaflet. C.I.4 -Change(s) in the SPC,Labelling or PL due to newquality,preclinical,clinicalorpharmacovigilance data C.I.4 -Change(s) in the SPC,Labelling orPL due to newquality,preclinical,clinicalorpharmacovigilance data C.I.4-Change(s)intheSPC,LabellingorPLdue to new quality,preclinical,clinicalorpharmacovigilance data C.I.4 -Change(s)in the SPC,Labelling orPL due to newquality,preclinical,clinicalorpharmacovigilance   |            |     | motherswereexposed atlevels(Auc)ofplasmaranolazine similartoexpectedhumanlevels.Inrats,noeffectsin fetuseswasnotedwhenmotherswereexposedto2-fold greaterlevels(Auc)thanexpectedinhumans,whereas decreasedfetalweightandreducedossificationwere observedwhentheexposureof motherswas7.5-fold than those obtained inhumans.Post-natal mortalityofpupswas notrecordedwhentheexposureofnursingmotherswas 1.3fold higherthan inexpected humans,whereasat 3-fold higherexposurepost-natalmortalitywasrecorded, concomitantwithevidenceofmilkexcretionofranolazinein rats.Noadverseeffectsonnewbornratswereobservedat levelsofexposuressimilartothoseobservedinhumans.   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0058/G | This was an applicationfora group of variations. B.I.a.1.a-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAs-The proposedmanufacturerispartofthesame pharmaceuticalgroup asthecurrently approved manufacturer B.I.a.1.a-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAS-The proposedmanufacturerispartofthesame                                                                                                                                                                                                                                                                                                            | 18/03/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | manufacturer B.1.b.1.d-Change in the specificationparameters and/orlimitsof anAs,starting material/intermediate/reagent-Deletionofanon- significant specification parameter(e.g. deletion of an obsoleteparameter)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                                                    |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------------------------|
| IB/0056/G   | Thiswasanapplicationforagroupofvariations. B.I.a.1.z-Change in the manufacturerof AS orofa startingmaterial/reagent/intermediateforAs-Other variation B.I.a.1.z-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAs-Other variation B.I.a.4.c-Changetoin-processtestsorlimits appliedduringthemanufactureoftheAs-Deletion ofanon-significantin-processtest B.I.a.4.c-Change toin-processtests orlimits appliedduringthemanufactureoftheAs-Deletion ofanon-significantin-processtest B.I.b.1.d-Change in the specification parameters and/orlimitsof anAs,starting material/intermediate/reagent-Deletionofanon- significantspecificationparameter(e.g.deletionof an obsoleteparameter) B.I.b.2.a-ChangeintestprocedureforAsor startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure | 05/12/2018 | n/a        |                                                    |
| PSUSA/2611/ | PeriodicSafetyUpdateEu Singleassessment-                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 20/09/2018 | 22/11/2018 | RefertoScientificconclusionsandgroundsrecommending |

<div style=\"page-break-after: always\"></div>

| 201801      | ranolazine                                                                                                                                                                                                                                                                                                                                                                           |            |            |                            | thevariationto termsof theMarketingAuthorisation(s)'for PSUSA/2611/201801.                                                                      |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0055/G   | This was an applicationfora group of variations. B.lL.b.4.a-Change in the batch size (including batch sizeranges)ofthefinishedproduct-Upto10-fold comparedtotheoriginallyapprovedbatchsize B.ll.b.3.z-Changeinthemanufacturingprocessof thefinishedorintermediateproduct-Othervariation B.ll.b.3.z-Changeinthemanufacturingprocessof thefinishedorintermediateproduct-Othervariation | 01/10/2018 | n/a        |                            |                                                                                                                                                 |
| 1/0053      | B.I.a.1.b-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAS- IntroductionofamanufactureroftheASsupported by an ASMF                                                                                                                                                                                                                                        | 12/10/2017 | n/a        |                            |                                                                                                                                                 |
| IAIN/0052/G | This was an applicationfora group of variations. A.5.a-Administrativechange-Changeinthename and/oraddressofamanufacturer/importer responsibleforbatchrelease B.Il.d.1.h-Changeinthespecificationparameters and/orlimitsofthefinishedproduct-Updateofthe dossiertocomplywiththeprovisionsofanupdated generalmonographofthePh.Eur.forthefinished product                               | 03/08/2017 | 20/12/2017 | Annex II, Labelling and PL |                                                                                                                                                 |
| 1/0051      | Updateofsections4.8and5.1oftheSmPCinorder toreflectthedatafromthefinalcsRfromstudy RIVER-PCI;aPhase3,Randomized,Double-Blind,                                                                                                                                                                                                                                                        | 15/12/2016 | 20/12/2017 | SmPC,Annex ⅡI and PL       | In a phase 3,double-blind,placebo-controlled,event- driventrial(RIVER-PCI)in2604patientsaged≥18years with ahistoryof chronicanginaandincomplete |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | Placebo-ControlledStudyoftheEffectsofRanolazine onMajorAdverseCardiovascularEventsinSubjects withaHistoryofChronicAnginawhoUndergo PercutaneousCoronaryInterventionwithIncomplete Revascularization.Inaddition,theMAHtookthe opportunitytoupdate the details ofthe local representativeinBulgariainthePackageLeafletand tobringtheAnnexⅡIinlinewith theQRDtemplate version 9.1. C.I.4-Change(s)in theSPC,LabellingorPLdueto newquality,preclinical,clinicalorpharmacovigilance data   |            |     | revascularisationafterpercutaneouscoronaryintervention (PCI)patientswereup-titratedto1oo0mgtwicedaily (dosagenot approvedin the current SmPC).No significant differenceoccurredinthecompositeprimaryendpoint (timetofirstoccurrenceofischaemia-driven revascularisation orischaemia-drivenhospitalisation withoutrevascularisation)intheranolazinegroup(26.2%) versustheplacebogroup(28.3%),hazardratio0.95,95% CI 0.82-1.10p=0.48.The risk of all cause mortality,CV deathor major adverse cardiovascularevents(MAcE) and heartfailurehospitalisationwassimilarbetweentreatment groups in the overall population; however, MACE were reportedmorefrequentlyinpatients≥75yearstreated withranolazine comparedwithplacebo(17.0%vs11.3%, respectively);inadditiontherewasanumericalincreasein all cause mortalityin in patients ≥75 years(9.2%vs. 5.1%,P = 0.074). Anincreasedincidenceofadverseeventswasseenamong ranolazinetreatedpatientsintheRIVER-PCItrialwhere patientswithincompleterevascularizationpost-PCIwere givenranolazineupto1oo0mgtwicedailyorplacebofor approximately70 weeks.In this study, there was ahigher reportingrateforcongestive heartfailureintheranolazine group (2.2% vs 1.0% in placebo).Also,transientischemic attackoccurredmorefrequentlyinpatientstreatedwith ranolazine1ooomgtwicedailycomparedwithplacebo (1.0%vs0.2%,respectively);however,theincidence of strokewassimilarbetweentreatmentgroups(ranolazine   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0050/G | Thiswas an applicationfora groupof variations.                                                                                                                                                                                                                                                                                                                                                                                                                                        | 19/02/2016 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                    | B.Ia.1.z-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAs-Other variation B.I.d.1.a.4-StabilityofAS-Changeinthere-test period/storage period -Extension or introduction ofa re-testperiod/storageperiodsupportedbyrealtime data                                                                                      |            |            |             |                                                                                                                                             |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2611/ 201501 | PeriodicSafetyUpdateEuSingleassessment- ranolazine                                                                                                                                                                                                                                                                                              | 24/09/2015 | 19/11/2015 | SmPC and PL | PleaserefertoRanexaPSUSA/00002611/201501EPAR: Scientificconclusionsandgroundsrecommendingthe variationtothetermsofthemarketingauthorisation |
| IA/0048/G          | This was an applicationfora group of variations. A.4-Administrativechange-Changeinthename and/oraddressofamanufactureroranAsMFholder orsupplieroftheAs，startingmaterial,reagentor intermediateusedinthemanufactureoftheASor manufacturerofanovelexcipient A.7-Administrative change-Deletionof manufacturing sites                              | 03/02/2015 | n/a        |             |                                                                                                                                             |
| IB/0046/G          | Thiswasanapplicationforagroupofvariations. B.Ia.1.f-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAs- Changestoqualitycontroltestingarrangementsfor theAs-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.a.2.e-Changesin themanufacturing processof theAs-Minor changeto therestrictedpartofan | 08/10/2014 | n/a        |             |                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|             | B.1.b.1.d-Change in the specificationparameters and/or limits of an As, starting material/intermediate/reagent-Deletionofanon- significant specification parameter(e.g.deletion of anobsoleteparameter)                                                                                                                                                                                                               |            |            |             |                                                     |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------|
| IAIN/0047/G | This was an applicationfora group of variations. B.lL.a.1.a -Change or additionofimprints,bossing orothermarkingsincludingreplacement,oraddition of inksused for productmarking-Changes in imprints,bossingorothermarkings B.ll.e.4.a-Changeinshapeordimensionsofthe containerorclosure(immediatepackaging)-Non- sterile medicinal products                                                                           | 06/08/2014 | 08/07/2015 | SmPC and PL |                                                     |
| IB/0045/G   | Thiswasanapplicationforagroupofvariations. B.I.a.2.e-Changesinthemanufacturingprocessof theAs-Minorchangetotherestrictedpartofan ASMF B.I.a.3.a-Changeinbatch size(includingbatchsize ranges)ofASorintermediate-Upto10-fold increasecomparedtotheoriginallyapprovedbatch size B.I.a.3.a-Changeinbatch size(includingbatchsize ranges)ofASorintermediate-Upto10-fold increasecomparedtotheoriginallyapprovedbatch size | 10/02/2014 | n/a        |             |                                                     |
| PSUV/0043   | PeriodicSafety Update                                                                                                                                                                                                                                                                                                                                                                                                 | 19/09/2013 | 13/11/2013 | SmPC and PL | RefertoScientificconclusions andgroundsrecommending |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                                | thevariationtotermsoftheMarketingAuthorisation(s)'for PSUV/0043.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0044 | B.I.a.3.a-Change in batch size(includingbatch size ranges)ofASorintermediate-Upto10-fold increase compared to theoriginally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 25/10/2013 | n/a        |                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| N/0042  | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 09/10/2013 | 08/07/2015 | PL                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| I/0038  | Updateofsection4.5oftheSmPCinordertoinclude informationregardingdrug-druginteractions: ranolazine/atorvastatineandranolazine/metformin. Updateofsections:4.8oftheSmPCtoinclude informationon\"co-ordination abnormal\",\"gait disturbance',\"dysuria\"，\"urinaryretention\"and4.7of theSmPCtoincludeinformationon\"coordination abnormal\"and\"diplopia\".The above changeswere introducedfollowingtherecommendationsfromthe ARforPSUR7.ThePackageLeafletwasupdated accordingly.Furthermore,thePIisbeingbroughtin linewiththeQRDtemplateversion8.3. Inaddition,the statementregardingPatientAlert Card(PAC）inAnnexICwasupdatedtoreflectthe factthatthe exact wording ofthePAcispresented in AnnexlIA.Inaddition,thetextofthePACinAnnex IIAwasupdatedtoincludethereferencetostatins andtacrolimusinteractions,followingthe recommendationsintheARforRanexa/Il/30. C.I.3.b-Implementationof change(s)requested | 25/04/2013 | 13/11/2013 | SmPC,Annex Ⅱ, Labelling and PL | Section4.8oftheSmPCwasupdatedwithdatafrom clinical studiesandfrompost-marketingexperience regardingthefollowing adverse drugreactions(ADRs): 'coordinationabnormal','gait disturbance','paraesthesia', diplopia'and`urinaryretention'.Inaddition,ADRs 'coordinationabnormal'and`diplopia'wereaddedtosection 4.7ofthe SmPC.These additions donotrepresentnew areasofconcernsforthisproductbutareseenas complementarytosimilarADRsincludedalreadyearlierin theSmPC. Also,threeinvivointeractionstudiesweresubmittedto evaluatetheeffectofranolazineonpharmacokineticsof metformin(2 studies)and atorvastatin (1 study).The resultsofthesestudiesindicatedthatranolazinemaycause aclinicallyrelevantinteractionwithmetformin(anocT2 substrate)butnotwithatorvastatin.Theinformationabout thesedrug-druginteractions(ranolazine/metforminand ranolazine/atorvastatin)wasincludedinsection4.5ofthe SmPC. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | followingthe assessmentofanUsR,classlabelling,a PSUR,RMP,FUM/SO，datasubmittedunderArticle 45/46,oramendmentstoreflectaCoreSPC- Change(s)withnewadditionaldatasubmittedbythe MAH                                                                                                                                                              |            |            |                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0041/G | Thiswasanapplicationforagroupofvariations. B.Il.b.1.a-Replacementoradditionofa manufacturing sitefortheFp-Secondarypackaging site B.Il.b.1.b-Replacementoradditionofa manufacturing site for the FP - Primary packaging site B.ll.b.2.b.2-Change tobatch release arrangements andqualitycontroltestingoftheFP-Includingbatch control/testing | 03/04/2013 | 13/11/2013 | AnnexII and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| R/0040      | Renewalofthemarketingauthorisation.                                                                                                                                                                                                                                                                                                          | 17/01/2013 | 06/03/2013 | AnnexIⅡI       | In thepivotal studiesranolazine hasshown toreduce, alone orincombinationwithotheranti-angina drugs,the numberofangina attacks and toimproveexercise toleranceinpatients with chronic angina without clinically significanteffectsonblood pressure andheartrate. Hypotensionis anuncommonADRandjust afewreportsof bradycardiahavebeencollectedinthepost-marketing surveillance.TheeffectsinethnicitiesotherthanCaucasian arestilltobeevaluated,asforpregnantandlactating women. Ranolazinehasacomplexpharmacokineticprofilewith |

<div style=\"page-break-after: always\"></div>

|        |                                                                                                                                                                                                                                                                           |            |            | inhibitors,P-gpinhibitors,CYP2D6inhibitors,patientwith CYP2D6poormetaboliserstatus(PM),patients withrenal impairmentorhepaticimpairment.Exposureis alsohigher in patients inthe lower weight range and in the elderly. Carefuldosetitrationissuggestedinthesesub-groupsand arecommendationtoreducethedoseincaseofpoor tolerabilityhasbeenintroducedintheSmPC. Ranolazine canbedescribedtohave anarrowtherapeutic window.Theriskfor significant pharmacokinetic interactionsisprobablygreaterinthe\"realworld\" comparedtoaclinicaltrialsetting,sinceranolazineislikely tobeused asa\"lastchance\"drugtopresumablymore fragilepatientstreatedwithmultipledrugsandwithother concomitantdiseases.It isveryimportantthatthedosing instructionispreciseandcorrect andtakesinto account thatthereareseveralpatientgroupsthatwherecautious titrationofthedoseisneeded. Followingtheassessmentofthepostmarketingexperience withranolazinefromthemarketingauthorisationtheCHMP recommendedthattherenewalbegrantedwithunlimited validity.   |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1/0036 | Additionofanewmanufacturerwithtwo manufacturing sitefortheproduction ofthedrug substance.ThatissupportedbyanASMF. B.I.a.1.b-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAS- IntroductionofanewmanufactureroftheAsthatis supported by an ASMF | 15/11/2012 | 15/11/2012 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| IA/0039   | A.7-Administrative change-Deletion of manufacturingsites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 10/10/2012   | 29/10/2012   | Annex II and PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0037   | B.Il.f.1.z-StabilityofFP-Changein the shelf-life or storage conditionsofthefinishedproduct-Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/08/2012   | n/a          |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0035   | B.ll.f.1.z-Stabilityof FP-Change in the shelf-life or storageconditionsofthefinishedproduct-Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 08/06/2012   | n/a          |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0033   | B.Il.f.1.b.1-StabilityofFP-Extensionof the shelf lifeof thefinishedproduct-Aspackagedforsale (supportedbyrealtimedata)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 13/04/2012   | 25/10/2012   | SmPC              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 1/0030    | TheMAHproposedtheupdateofsection4.5ofthe SmPCinordertoaddinformationoninteractionwith tacrolimus and statins.In addition,sections4.6and 5.3weremodifiedbasedontheinformationfrom previouslysubmitted animalreproductiontoxicity studies.Furthermore small modifications were introducedtosection4.8regardingacuterenal failure.Section4.7wasmodifiedinlinewith variationIl/029.Furthermore,theMAHproposed this opportunitytobring sections 4.1,4.2,4.6 and 5.2oftheSmPCinlinewith theQRDtemplate version8.PackageLeafletwasproposedtobe updatedinaccordance.In addition,theMAH tookthe opportunitytoupdate the listof local representatives in thePackageLeaflet. | 16/02/2012   | 19/03/2012   | SmPC and PL       | Thisvariationconcernsnewinformationontheinteractions occurringbetweenranolazineandstatinsandranolazine and tacrolimus,respectively.Therevisedinformationon theinteractionbetweenranolazineandstatins/ranolazine andtacrolimushasbeenintroducedonthebasisofa cumulative review on clinical studies and post-marketing IndividualCaseSafetyReports.Informationthatdose adjustmentsofsomestatinslikesimvastatin andlovastatin andCYP3A4substrateswithanarrowtherapeuticrange (e.g.,ciclosporin,tacrolimus,sirolimus,everolimus)may berequired asranolazinemayincreaseplasma concentrationsofthese drugs. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | C.I.3.b-Implementationof change(s)requested following the assessmentofan UsR, class labelling,a PSUR,RMP，FUM/SO,datasubmittedunderArticle 45/46,oramendmentstoreflectaCoreSPC- Change(s) with new additional data submitted bythe MAH                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |     |             |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| IAIN/0034 | C.I.9.i-Changes to an existing pharmacovigilance system as described in the DDPs - Change(s) to a DDPSfollowingtheassessmentofthesameDDPSin relationtoanothermedicinalproductofthe same                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 07/03/2012 | n/a | MAH         |
|           | This was an applicationfora group of variations. C.I.9.a-Changes to an existingpharmacovigilance systemasdescribedintheDDPS-Changeinthe QPPV C.I.9.h-Changestoanexistingpharmacovigilance system as describedintheDDPS-Other change(s) totheDDpsthatdoesnotimpactontheoperationof thepharmacovigilancesystem C.I.9.c-Changes to an existingpharmacovigilance system as described in the DDPS -Change ofthe back-upprocedureoftheQPPV C.I.9.e-Changes to anexisting pharmacovigilance system as describedintheDDPS-Changesin the major contractual arrangements withotherpersons ororganisationsinvolvedinthefulfilmentof pharmacovigilanceobligations anddescribedinthe | 29/11/2011 | n/a | IAIN/0031/G |

<div style=\"page-break-after: always\"></div>

| IA/0032   | A.5.b-Administrative change-Change inthe name and/oraddressofamanufacturerofthefinished product,including qualitycontrol sites(excluding manufacturerforbatchrelease)                                                                                                                                                                                                                                                               | 03/11/2011   | n/a        |                      |        |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------|--------|
|           | UpdateofSection4.8oftheSmPCtoinclude confessional state and hallucination underpsychiatric disorders.Asa consequenceSection4ofthePLwas alsoupdated.Inaddition,EMEAwasreplacedwith EMAintheEMAname/address,telephonenumberof thelocalrepresentativeinBulgariawasupdatedand theversionnumberofthepharmacovigilancesystem inAnnexIIBwasdeleted. C.I.z -Changes(Safety/Efficacy)of Human and VeterinaryMedicinalProducts-Othervariation | 14/04/2011   | 17/06/2011 | SmPC,Annex ⅡI and PL | 1/0029 |
| 1/0028    | UpdateofSection4.8Undesirableeffectsfollowinga reviewofthe 4thPSUR. C.I.3.b-Implementationof change(s)requested followingthe assessmentofan UsR,classlabelling,a PSUR,RMP,FUM/SO，datasubmittedunderArticle 45/46,oramendmentstoreflectaCoreSPC- Change(s)withnewadditionaldatasubmittedbythe MAH                                                                                                                                    | 20/01/2011   | 21/02/2011 | SmPC                 |        |
| 1/0026    | Tointroduceanadditional manufacturing siteforthe production of the active substance.                                                                                                                                                                                                                                                                                                                                                | 18/11/2010   | 26/11/2010 |                      |        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.Ia.1.c-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAs-The proposedmanufacturerusesasubstantiallydifferent routeofsynthesisormanufacturingconditions                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                                 |                                                                                                                                                                                                                                                                                                     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0025/G | This was an applicationfora group of variations. To add Menarini-Von Heyden GmBH (Leipziger Strasse7-13,D-01079 Dresden,Germany)as an additionalmanufactruingsiteforbulkproductionof the durg product. Tochangethebossingofthetabletsduetothenew manufacturer B.lL.b.1.e-Replacementoradditionof a manufacturing site for the FP - Site where any manufacturing operation(s)takeplace,exceptbatch- release,batchcontrol,primaryandsecondary packaging,fornon-sterilemedicinalproducts B.lL.a.1.a-Change or additionofimprints,bossing orothermarkingsincludingreplacement,oraddition of inks usedforproduct marking-Changes in imprints,bossingor othermarkings | 13/07/2010 | n/a        | SmPC and PL                     |                                                                                                                                                                                                                                                                                                     |
| 1/0023    | UpdateofSummaryofProductCharacteristics, AnnexI,PatientAlertCardandPackageLeafletand Annex IV. UpdateofSummaryofProductCharacteristics, Labelling andPackageLeaflet                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 18/02/2010 | 10/05/2010 | SmPC, Annex I, Labelling and PL | Followingresultsofaninvivodrug-druginteractionstudy evaluatingtheeffectofRanolazineonthepharmacokinetic ofmetoprolol,theSPCsection4.5isupdatedtoaddthat Ranexa750mgtwicedailyincreasedplasma concentrationsofmetoprololby1.8-fold.Clarificationon exposuretootherCYP2D6substratesis alsointroduced. |

<div style=\"page-break-after: always\"></div>

|         |                                                                         |            |     |                        | Furthermore,theincidenceofarrhythmiasintheMERLIN- TIMI 36study is amendedin section 5.1. Inaddition,quinidineisremovedfromsection4.5and patientcardtoavoidconfusionforprescribers,sinceitis contraindicatedinsection4.3.ThePatientAlertCardand Package Leaflet are updated accordingly Inaddition,amendments areintroduced bythe CHMPin annexⅡl, SmPC and PatientAlertcard(PAC)forRanexa (ranolazine)concerningquinidine.SPCstatementsin section4.5wereconsideredconfusingandletprescribers thinkthataconcomitantuseofranolazineandquinidineis possible,whereastheuse ofquinidineiscontraindicated withRanexa.Therefore,theCHMPconsideredthat quinidineshould beremovedfromthelistofP-gpinhibitors insection4.5oftheSPC.Thissamecontradictionwasalso presentin the Annex II, PatientAlert Card (in labelling). Finally,minorupdateofthePIarerequestedforsome languages.   |
|---------|-------------------------------------------------------------------------|------------|-----|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0024 | IA_o7_a_Replacement/add.ofmanufacturingsite: Secondarypackagingsite     | 13/01/2010 | n/a |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0022 | IB_34_b_01_Changeincolour/flavour-Increase or addition:colouring system | 11/12/2009 | n/a | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| IB/0021 | IB_33_Minorchangeinthemanufactureofthe                                  | 15/10/2009 | n/a |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|         | finished product                                                                         |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------|------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I/0020  | UpdateofDDPS(Pharmacovigilance)                                                          | 23/07/2009 | 25/08/2009 | AnnexⅡI                | TheMAHsubmittedarevisedDDPS.Consequentlythe versionnumberis amendedinAnnexI.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 1/0019  | UpdateofSummaryofProductCharacteristics                                                  | 23/07/2009 | 25/08/2009 | Annex II and Labelling | AnnexMIAisamended byintroducingofthepatientalert cardintoLabelling.Consequently,theAnnexⅡIhasbeen updated.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 1/0018  | UpdateofSummaryofProductCharacteristics and PackageLeaflet                               | 23/07/2009 | 25/08/2009 | SmPC and PL            | FurthertoarequestbytheEMEAregardingpostmarketing casesofrenalfailureintheEudravigilancedatabase,the CHMPagreedtoaddthefollowinginformationregarding acuterenalfailureinSection4.8of theSPC: In this long term study,acuterenalfailure was also reportedwithanincidencelessthan1%inplaceboand ranolazine patients.[.] Post Marketing experience: Inpostmarketingexperience,therehavebeenreportsof acute renalfailure,includinginpatients with pre-existing mildtomoderaterenalimpairmentand/ortaking concomitantmedicationsthatareknown tointeract with ranolazine (see sections 4.4 and 4.5). ThePackageLeafletisupdatedaccordingly. |
| IA/0017 | IA_08_b_01_ChangeinBR/QC testing-repl./add. manuf.responsibleforBR-notincl.BC/testing    | 29/04/2009 | n/a        | AnnexII and PL         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0016 | IA_08_b_02_Change inBR/QC testing-repl./add. manuf. responsible for BR -incl. BC/testing | 29/04/2009 | n/a        | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IA/0015   | IA_08_b_01_ChangeinBR/QC testing-repl./add. manuf.responsibleforBR-notincl.BC/testing                                                                 | 29/04/2009   | n/a        | Annex II and PL        |                                                                                           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------------------------------------------------------------|
| IB/0013   | IB_17_a_Changeinre-testperiodoftheactive substance                                                                                                    | 16/04/2009   | n/a        |                        |                                                                                           |
| IA/0010   | IA_o7_a_Replacement/add.ofmanufacturingsite: Secondarypackagingsite IA_07_b_01_Replacement/add.ofmanufacturing site:Primarypackagingsite-Solidforms   | 14/04/2009   | n/a        |                        |                                                                                           |
| IA/0009   | IA_o7_a_Replacement/add.of manufacturingsite: Secondarypackagingsite IA_07_b_01_Replacement/add.ofmanufacturing site:Primarypackaging site-Solidforms | 14/04/2009   | n/a        |                        |                                                                                           |
| IA/0014   | IA_08_a_Change in BR/QC testing - repl./add. of batchcontrol/testingsite                                                                              | 06/04/2009   | n/a        |                        |                                                                                           |
| IA/0012   | IA_36_b_Changein shape or dimensionsofthe container/closure-otherpharm.forms                                                                          | 06/04/2009   | n/a        |                        |                                                                                           |
| T/0008    | TransferofMarketingAuthorisation                                                                                                                      | 19/12/2008   | 25/02/2009 | SmPC, Labelling and PL | TransferfromCVTherapeuticsEuropeLimitedtoMenarini International OperationsLuxembourg S.A. |
| IB/0007   | IB_41_a_02_Change in pack size - change in no. of units outsiderange of appr.packsize                                                                 | 30/10/2008   | 30/10/2008 | SmPC, Labelling and PL |                                                                                           |
| IB/0006   | IB_41_a_02_Change inpack size-change in no.of unitsoutsideranqe of appr.packsize                                                                      | 30/10/2008   | 30/10/2008 | SmPC, Labellinqand     |                                                                                           |

<div style=\"page-break-after: always\"></div>

|         |                                                                                     |            |            | PL                              |
|---------|-------------------------------------------------------------------------------------|------------|------------|---------------------------------|
| IB/0005 | IB_41_a_02_Change inpack size-change in no.of units outsiderangeofappr.packsize     | 30/10/2008 | 30/10/2008 | SmPC, Labelling and PL          |
| IB/0004 | IB_41_a_02_Change inpack size-change in no.of units outsiderangeofappr.packsize     | 30/10/2008 | 30/10/2008 | SmPC, Labelling and PL          |
| IB/0003 | IB_41_a_02_Change in pack size-changein no.of units outside range of appr.pack size | 30/10/2008 | 30/10/2008 | SmPC, Labelling and PL          |
| IB/0002 | IB_41_a_02_Change inpack size-change in no.of unitsoutside range of appr.pack size  | 30/10/2008 | 30/10/2008 | SmPC, Labelling and PL          |
| IB/0001 | IB_02_Changein the nameofthemedicinalproduct                                        | 11/08/2008 | n/a        | SmPC,Annex ⅡI, Labelling and PL |